Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744214 | 0.79 | HRH3 (0.33) | — | |
| SCHEMBL2677896 | 0.70 | CHRNA7 (0.43) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2676639 | 0.67 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2677056 | 0.66 | KDM4E (0.42) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2677317 | 0.65 | ACACB (0.49) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL3391442 | 0.65 | CHRNA7 (0.45) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2678166 | 0.65 | SCD (0.48) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1449402 | 0.65 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2677278 | 0.64 | RAB9A (0.39) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1744102 | 0.64 | HSD11B1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | claimed |
| EP-2246352-A1 | Novel diazabicyclic aryl derivatives and their medical use | NeuroSearch AS (DK) | 2010-11-03 | — | — | EP | claimed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | claimed |
| EP-1963323-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-09-03 | — | — | EP | claimed |
| WO-2007065892-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | claimed |
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2246352-A1 | Novel diazabicyclic aryl derivatives and their medical use | NeuroSearch AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | disclosed |
| EP-1963323-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065892-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | ACHE, CHRNA6, CHRNA10 | CHRNA7 6/4885HTR3A 47/4885CHRNB4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.